Based on the above results, we propose a strategy for the use of ovarian tumour histology in the assessment of germline BRCA1 and BRCA2 VUS interpretation under the strict rules of the ACMG/AMP system, based on patient characteristics and available information (Table 3). The gene discussed is BRCA2; the disease is ovarian neoplasm.